Table 5.
Summary of linear dose-response meta-analyses of prospective studies on cheese intake and CVD, CHD, stroke, T2DM, and CRC.
| Authors, Year, Reference | No. of Studies | Each Increment Intake Per Day | RR (95% CI) | I2 Statistic | p-Value for Heterogeneity | Begg’s or Egger’s Test p-Value |
|---|---|---|---|---|---|---|
| Chen 2017 [44] | 7 | 50 g | CVD 0.92 (0.83–1.02) | 16.90% | 0.301 | >0.100 |
| Guo 2017 [33] | 11 | 10 g | CVD 0.98 (0.95–1.00) | 82.60% | <0.001 | NR |
| Chen 2017 [44] | 8 | 50 g | CHD 0.90 (0.84–0.95) | 0.00% | 0.444 | 0.170/0.040 |
| Guo 2017 [33] | 10 | 10 g | CHD 0.99 (0.97–1.02) | 40.30% | 0.089 | 0.273 |
| Chen 2017 [44] | 5 | 50 g | Stroke 0.94 (0.84–1.04) | 63.70% | 0.026 | >0.10 |
| de Goede 2016 [35] | 7 | 40 g | Stroke 0.97 (0.94–1.01) | 31.20% | 0.179 | NR |
| Aune 2013 [36] | 8 | 50 g | T2DM 0.92 (0.86–0.99) | 0.00% | 0.790 | 0.740 |
| Gao 2013 [37] | 7 | 30 g | T2DM incidence 0.80 (0.69–0.93) | 59.00% | 0.020 | NR |
| Gijsbers 2016 [38] | 13 | 10 g | T2DM incidence 1.00 (0.99–1.02) | 61.70% | 0.002 | 0.880 |
| Aune 2012 [39] | 7 | 50 g | CRC 0.96 (0.83–1.12) | 28.00% | 0.220 | NR |
| Vieira 2017 [20] | 7 | 50 g | CRC 0.94 (0.87–1.02) | 10.00% | 0.360 | NS |
CVD, cardiovascular disease; CHD, coronary heart disease; T2DM, type 2 diabetes mellitus; CRC, colorectal cancer; RR, relative risk; NR, not reported; NS, not significant.